IL94983A0 - Sustained release formulations of water soluble peptides - Google Patents

Sustained release formulations of water soluble peptides

Info

Publication number
IL94983A0
IL94983A0 IL94983A IL9498390A IL94983A0 IL 94983 A0 IL94983 A0 IL 94983A0 IL 94983 A IL94983 A IL 94983A IL 9498390 A IL9498390 A IL 9498390A IL 94983 A0 IL94983 A0 IL 94983A0
Authority
IL
Israel
Prior art keywords
water soluble
sustained release
release formulations
soluble peptides
peptides
Prior art date
Application number
IL94983A
Other versions
IL94983A (en
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz Ag filed Critical Sandoz Ag
Priority to IL11228690A priority Critical patent/IL112286A/en
Priority to IL14168290A priority patent/IL141682A/en
Publication of IL94983A0 publication Critical patent/IL94983A0/en
Priority to IL11228695A priority patent/IL112286A0/en
Publication of IL94983A publication Critical patent/IL94983A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL9498390A 1989-07-07 1990-07-05 Somatostatin and its analogs and sustained release formulations of such water soluble peptides IL94983A (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
IL11228690A IL112286A (en) 1989-07-07 1990-07-05 Process for the production of a microparticle and microparticle obtained thereby
IL14168290A IL141682A (en) 1989-07-07 1990-07-05 Process for the production of microparticles using a water-immiscible organic solvent, and a sustained release formulation comprising said microparticles
IL11228695A IL112286A0 (en) 1989-07-07 1995-01-09 Process for the production of a microparticle and microparticle obtained thereby

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37702389A 1989-07-07 1989-07-07
US41134789A 1989-09-22 1989-09-22

Publications (2)

Publication Number Publication Date
IL94983A0 true IL94983A0 (en) 1991-06-10
IL94983A IL94983A (en) 1999-08-17

Family

ID=27007654

Family Applications (3)

Application Number Title Priority Date Filing Date
IL9498390A IL94983A (en) 1989-07-07 1990-07-05 Somatostatin and its analogs and sustained release formulations of such water soluble peptides
IL13188190A IL131881A (en) 1989-07-07 1990-07-05 Sustained release formulation comprising octreotide in a polymeric carrier
IL13188090A IL131880A (en) 1989-07-07 1990-07-05 Process for the production of micro particles using a water-in-oil emulsion, and micro particles obtained thereby

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL13188190A IL131881A (en) 1989-07-07 1990-07-05 Sustained release formulation comprising octreotide in a polymeric carrier
IL13188090A IL131880A (en) 1989-07-07 1990-07-05 Process for the production of micro particles using a water-in-oil emulsion, and micro particles obtained thereby

Country Status (27)

Country Link
JP (5) JPH0832624B2 (en)
KR (2) KR100303681B1 (en)
AT (1) AT406225B (en)
AU (2) AU641407B2 (en)
BE (1) BE1004486A3 (en)
CA (1) CA2020477C (en)
CH (1) CH685230A5 (en)
CY (1) CY1965A (en)
DE (2) DE4042752B4 (en)
DK (1) DK175849B1 (en)
FI (3) FI108611B (en)
FR (1) FR2649319A1 (en)
GB (2) GB2234896B (en)
GR (1) GR1001121B (en)
HK (2) HK97695A (en)
HU (2) HU221294B1 (en)
IE (2) IE64216B1 (en)
IL (3) IL94983A (en)
IT (1) IT1241460B (en)
LU (1) LU87764A1 (en)
MY (1) MY106722A (en)
NL (1) NL195027C (en)
NO (2) NO302928B1 (en)
NZ (1) NZ234384A (en)
PT (1) PT94628B (en)
SE (1) SE512992C2 (en)
SG (1) SG26416G (en)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4990336A (en) * 1989-02-08 1991-02-05 Biosearch, Inc. Sustained release dosage form
YU48420B (en) * 1991-03-25 1998-07-10 Hoechst Aktiengesellschaft PROCEDURE FOR OBTAINING BIOLOGICAL DEGRADABLE MICROPARTICLES WITH LONG TERM ACTION
CH683149A5 (en) * 1991-07-22 1994-01-31 Debio Rech Pharma Sa Process for the preparation of microspheres of a biodegradable polymeric material.
US6013853A (en) * 1992-02-14 2000-01-11 The University Of Texas System Continuous release polymeric implant carrier
US5876452A (en) * 1992-02-14 1999-03-02 Board Of Regents, University Of Texas System Biodegradable implant
DE4218510A1 (en) * 1992-06-02 1993-12-09 Pharmatech Gmbh Process for the preparation of biodegradable polyesters
AU4198793A (en) † 1992-07-24 1994-01-27 Takeda Chemical Industries Ltd. Microparticle preparation and production thereof
EP0626170A3 (en) * 1993-05-10 1996-03-27 Sandoz Ltd Stabilisation of pharmacologically active compounds in sustained release compositions.
GB9310781D0 (en) * 1993-05-25 1993-07-14 Davis Stanley S Preparation of microparticles
US5603960A (en) * 1993-05-25 1997-02-18 O'hagan; Derek T. Preparation of microparticles and method of immunization
DK0729357T3 (en) 1993-11-19 2005-06-06 Janssen Pharmaceutica Nv Microencapsulated 1,2-benzazoles
EP0862419B2 (en) 1995-11-09 2010-11-17 Microbiological Research Authority Microencapsulated dna for vaccination and gene therapy
US6270795B1 (en) 1995-11-09 2001-08-07 Microbiological Research Authority Method of making microencapsulated DNA for vaccination and gene therapy
DE19545257A1 (en) 1995-11-24 1997-06-19 Schering Ag Process for the production of morphologically uniform microcapsules and microcapsules produced by this process
US5817343A (en) * 1996-05-14 1998-10-06 Alkermes, Inc. Method for fabricating polymer-based controlled-release devices
US5968895A (en) * 1996-12-11 1999-10-19 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
US6126919A (en) 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
GB9810236D0 (en) 1998-05-13 1998-07-08 Microbiological Res Authority Improvements relating to encapsulation of bioactive agents
US6632457B1 (en) * 1998-08-14 2003-10-14 Incept Llc Composite hydrogel drug delivery systems
US6226656B1 (en) 1998-11-12 2001-05-01 Sourcefinder, Inc. System and method for creating, generating and processing user-defined generic specs
US7107268B1 (en) 1998-11-12 2006-09-12 Printable Technologies, Inc. Centralized system and method for managing enterprise operations
US6204308B1 (en) 1999-03-01 2001-03-20 Novartis Ag Organic compounds
EP1044683A1 (en) * 1999-04-15 2000-10-18 Debio Recherche Pharmaceutique S.A. One-step dispersion method for the microencapsulation of water soluble substances
US6461631B1 (en) * 1999-11-16 2002-10-08 Atrix Laboratories, Inc. Biodegradable polymer composition
KR100392501B1 (en) * 2000-06-28 2003-07-22 동국제약 주식회사 Preparation Method for Sustained Release Microparticles by Multiple Emulsion Method and Micropartic les Thereof
US6824822B2 (en) * 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
JP2004516262A (en) 2000-12-21 2004-06-03 ネクター セラピューティクス Induced phase transition method for the production of microparticles containing hydrophilic activators
US20040097419A1 (en) * 2002-11-19 2004-05-20 Holger Petersen Organic compounds
PE20050285A1 (en) * 2003-06-24 2005-06-09 Novartis Ag PHARMACEUTICAL COMPOSITION INCLUDING CYCLIC ANALOGS OF SOMATOSTATIN
JP2008518881A (en) * 2003-07-18 2008-06-05 オークウッド ラボラトリーズ，エル．エル．シー． Prevention of molecular weight reduction, impurity formation and gelation of polymer in polymer composition
MY158342A (en) 2003-11-14 2016-09-30 Novartis Ag Pharmaceutical composition
JPWO2005082405A1 (en) * 2004-02-26 2007-10-25 独立行政法人科学技術振興機構 Sustained release fine particle preparation for protein drug injection and its production method
DE102004053373A1 (en) * 2004-11-02 2006-05-04 Justus-Liebig-Universität Giessen Invention relating to nano / meso-fiber anisometric particles in the form of nano / meso-fiber tubes, cables and their curved or branched modifications
KR100741867B1 (en) * 2005-07-05 2007-07-24 전북대학교산학협력단 Preparation method of double-layered sphere using oil-in-water and solvent evaporation
KR20130024987A (en) * 2005-12-22 2013-03-08 노파르티스 아게 Sustained release formulation comprising octreotide and two or more polylactide-co-glycolide polymers
KR100816065B1 (en) * 2006-11-27 2008-03-24 동국제약 주식회사 Preparation method of sustained-release microcapsules having good initial burst inhibiting property and the microcapsules thereby
CA2713339C (en) 2008-01-30 2017-01-17 Novartis Ag Sustained release formulation comprising octreotide and three linear polylactide-co-glycolide polymers
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
CA2813301A1 (en) * 2010-09-30 2012-04-05 Evonik Corporation Method for removing residual organic solvent from microparticles
WO2012044675A2 (en) * 2010-09-30 2012-04-05 Surmodics Pharmaceuticals, Inc. Emulsion method for preparing low residual solvent microparticles
TW201605488A (en) 2013-10-15 2016-02-16 大塚製藥股份有限公司 Drug for preventing and/or treating polycystic kidney disease
KR102464650B1 (en) 2016-05-03 2022-11-10 엘에스일렉트릭(주) Current limiting device of circuit breaker
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
CN110382052A (en) 2017-03-26 2019-10-25 Mapi医药公司 The copaxone store system of multiple sclerosis for therapeutic advance type form

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
CH649217A5 (en) * 1977-08-25 1985-05-15 Sandoz Ag BROMOCRIPTIN CONTAINING MICROCAPSULES.
US4622244A (en) * 1979-09-04 1986-11-11 The Washington University Process for preparation of microcapsules
US4293539A (en) * 1979-09-12 1981-10-06 Eli Lilly And Company Controlled release formulations and method of treatment
DE19375086I2 (en) * 1979-11-27 2003-01-09 Novartis Ag Polypeptides Process for their preparation pharmaceutical compositions containing these polypeptides and their use
US4389330A (en) * 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
PH19942A (en) * 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
US4675189A (en) * 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
DE3378250D1 (en) * 1982-04-22 1988-11-24 Ici Plc Continuous release formulations
CH656884A5 (en) * 1983-08-26 1986-07-31 Sandoz Ag POLYOLESTERS, THEIR PRODUCTION AND USE.
US4485101A (en) * 1983-10-11 1984-11-27 Administrators Of The Tulane Educational Fund Peptides
JPH0657658B2 (en) * 1985-04-11 1994-08-03 住友製薬株式会社 Sustained release formulation
JPS60100516A (en) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd Preparation of sustained release microcapsule
GB8331158D0 (en) * 1983-11-22 1983-12-29 British Telecomm Metal/semiconductor deposition
JPS60181029A (en) * 1984-02-29 1985-09-14 Toyo Jozo Co Ltd Preparation of sustained release preparation
CH660302A5 (en) * 1984-10-17 1987-04-15 Debiopharm Sa HETEROGENEOUS PHASE MICRO-ENCAPSULATION PROCESS OF WATER-SOLUBLE DRUG SUBSTANCES.
DE3678308D1 (en) * 1985-02-07 1991-05-02 Takeda Chemical Industries Ltd METHOD FOR PRODUCING MICROCAPSULES.
US4725577A (en) * 1985-04-25 1988-02-16 Administrators Of The Tulane Educational Fund Biologically active lysine containing octapeptides
CH665558A5 (en) * 1985-10-09 1988-05-31 Debiopharm Sa Phase sepn. prodn. of microcapsules for water soluble pharmaceuticals - using fluoro-substd. aliphatic hydrocarbon as non-solvent in the hardening stage
JP2539789B2 (en) * 1986-03-06 1996-10-02 日本原子力研究所 Process for producing sustained-release drug complex composed of polylactone
GB2193891B (en) * 1986-08-18 1990-07-25 Sandoz Ltd Nasal pharmaceutical composition containing a somatostatin anologue.
JPH0725689B2 (en) * 1986-10-07 1995-03-22 中外製薬株式会社 Sustained-release preparation containing granulocyte colony-stimulating factor
GB2209937B (en) * 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
CH672887A5 (en) * 1987-10-14 1990-01-15 Debiopharm Sa
DE3738228A1 (en) * 1987-11-11 1989-05-24 Hoechst Ag METHOD FOR PRODUCING BIODEGRADABLE MICRO-CAPSULES OF WATER-SOLUBLE PEPTIDES AND PROTEINS AND MICRO-CAPSULES OBTAINED BY THIS PROCESS
JP2653255B2 (en) * 1990-02-13 1997-09-17 武田薬品工業株式会社 Long-term sustained release microcapsules

Also Published As

Publication number Publication date
AU5874690A (en) 1991-01-10
GB2265311A (en) 1993-09-29
DK175849B1 (en) 2005-03-29
GR900100513A (en) 1991-12-10
NO302928B1 (en) 1998-05-11
HUT54037A (en) 1991-01-28
FR2649319B1 (en) 1994-12-09
DE4021517B4 (en) 2009-04-09
DK162590D0 (en) 1990-07-05
CA2020477C (en) 2000-11-21
JPH07285853A (en) 1995-10-31
IE64411B1 (en) 1995-08-09
FR2649319A1 (en) 1991-01-11
SE9002364L (en) 1991-01-08
PT94628A (en) 1991-03-20
JPH08198771A (en) 1996-08-06
NO903001D0 (en) 1990-07-05
GB2234896B (en) 1994-01-19
JP2001233897A (en) 2001-08-28
AU687553B2 (en) 1998-02-26
KR100303681B1 (en) 2002-05-16
NL195027B (en) 2003-08-01
IT1241460B (en) 1994-01-17
IL94983A (en) 1999-08-17
CY1965A (en) 1997-07-04
SG26416G (en) 1995-09-01
JP2931773B2 (en) 1999-08-09
HU221294B1 (en) 2002-09-28
ATA144090A (en) 1999-08-15
AT406225B (en) 2000-03-27
JPH07309897A (en) 1995-11-28
GB9014704D0 (en) 1990-08-22
JPH0368511A (en) 1991-03-25
NL195027C (en) 2003-12-02
NO983923D0 (en) 1998-08-26
SE512992C2 (en) 2000-06-12
FI20000059A (en) 2000-01-12
SE9002364D0 (en) 1990-07-05
NO983923L (en) 1991-01-08
CA2020477A1 (en) 1991-01-08
FI109334B (en) 2002-07-15
BE1004486A3 (en) 1992-12-01
IL131880A (en) 2001-12-23
GB2234896A (en) 1991-02-20
KR910002430A (en) 1991-02-25
IT9048113A1 (en) 1992-01-05
DE4042752B4 (en) 2009-05-07
NO320444B1 (en) 2005-12-05
DK162590A (en) 1991-01-08
HK97695A (en) 1995-06-23
AU2332195A (en) 1995-09-07
FI108611B (en) 2002-02-28
NO903001L (en) 1991-01-08
IE902435A1 (en) 1991-02-13
JPH0832624B2 (en) 1996-03-29
HU211602A9 (en) 1995-12-28
NL9001537A (en) 1991-02-01
IE64216B1 (en) 1995-07-26
FI903429A0 (en) 1990-07-06
HU903974D0 (en) 1990-11-28
CH685230A5 (en) 1995-05-15
LU87764A1 (en) 1992-03-11
FI109543B (en) 2002-08-30
PT94628B (en) 1997-06-30
MY106722A (en) 1995-07-31
FI20000060A (en) 2000-01-12
AU641407B2 (en) 1993-09-23
DE4021517A1 (en) 1991-01-17
HK197496A (en) 1996-11-08
IT9048113A0 (en) 1990-07-05
GB9306204D0 (en) 1993-05-19
GB2265311B (en) 1994-02-09
GR1001121B (en) 1993-04-28
IL131881A (en) 2001-12-23
KR100442931B1 (en) 2004-08-02
NZ234384A (en) 1994-05-26

Similar Documents

Publication Publication Date Title
GB2265311B (en) Sustained release formulations of water soluble peptides
PH30995A (en) Sustained release formulations of water soluble peptides.
IL87790A (en) Sustained release compositions containing water insoluble polypeptides
GB2230185B (en) Sustained release pharmaceutical compositions
ZA907492B (en) Stabilized aqueous formulations of small peptides
ZA904925B (en) Sustained release pharmaceutical compositions
GB2195893B (en) Sustained release pharmaceutical compositions
GB8812928D0 (en) Contraceptive methods & compositions
AP9000174A0 (en) Antiparasitical formulations
IL88148A0 (en) Somatotropin sustained release formulations
CY1844A (en) Sustained release formulations of water soluble peptides
ZA905327B (en) Sustained release formulations of water soluble peptides
GB2237839B (en) Powered release of connectors
IL131881A0 (en) Sustained release formulation comprising octreotide
IE890932L (en) Water soluble ibuprofen compositions
IE871503L (en) Sustained release formulations
GB8922061D0 (en) Controlled release formulations
ZA898470B (en) Sustained release preparations
IE893777L (en) Sustained release diltiazen formulation
GB8904109D0 (en) New formulations of chloramine
IE880658L (en) Sustained release compositions
GB8624214D0 (en) Sustained release pharmaceutical compositions
IE862339L (en) Disc-like sustained release formulations
NZ234086A (en) Preparation of tripeptide aldehydes
GB8908838D0 (en) Sustained release

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed